MMP9 and camptodactyly-arthropathy-coxa vara-pericarditis syndrome: The role of PC6 and HT5 on the treatment of CSAP included reducing the serum content of matrix metalloproteinase-9 (MMP-9), decreasing content and the equivalent block of coronary artery calcified plaque (CACP) and increasing heart rate variability (HRV) to improve the tension of cardiac autonomic nervous system.